Relapse after HSCT 2021 | The potential of TCRs for relapse management
Christoph Schmid, MD, University of Augsburg, Augsburg, Germany, talks on the potential of T-cell expressing receptors (TCRs) targeting a particular antigen for relapse prevention, highlighting a recent study reporting a 100% prevention rate in patients with high-risk acute myeloid leukemia (AML). This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
Transcript (edited for clarity)
TCRs are very interesting and very important technology, in particular because it can address intracellular proteins, result of tumor-type, tumor-typical mutations or new proteins. That’s a big advantage. So, this advantage is a restriction to certain HLA molecules. So far, we did not have so many convincing data with respect to relapse prevention. If you look into the reviews, most deal with technical problems or approaches how we can improve the efficacy...
TCRs are very interesting and very important technology, in particular because it can address intracellular proteins, result of tumor-type, tumor-typical mutations or new proteins. That’s a big advantage. So, this advantage is a restriction to certain HLA molecules. So far, we did not have so many convincing data with respect to relapse prevention. If you look into the reviews, most deal with technical problems or approaches how we can improve the efficacy. Quite recently, as I’ve shown in the talk, there was an impressive series of patients reported from Seattle with 100% prevention rate in a small group of high-risk AML patients. If this promise holds through, I think this will be, let’s say one of the most effective technologies that we have in the field.
Read more...
Disclosures
Christoph Schmid, MD, has received research and travel grants from Novartis, Roche, Abbvie and Neovii; honoraria and speakers bureau from Novartis, Roche, BMS and Eurocept; and is also on the advisory boards of Novartis, Daichii, Eurocept and Roche.
